Compare Medtronic PLC (MDT) vs Snap Inc (SNAP) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

Snap Inc. (SNAP) trades at $4.585, up 1.33% on the day, amid a bearish technical signal and mixed fundamentals. Revenue grew to $5.93 billion in 2025, but the company posted a net loss of $460.49 million, with a negative net margin of -6.72%. Recent news highlights the launch of high-priced AR glasses, which sparked investor concerns and a stock decline. The stock faces resistance near $5, with analyst consensus price target at $5.75, suggesting modest upside potential from current levels.

The outlook remains cautious; while cost-cutting and AR innovation offer long-term growth avenues, persistent losses, competitive pressures, and high debt levels pose significant risks. Investor sentiment is divided, with analysts mostly neutral to bullish, but the stock's performance hinges on achieving profitability and successful monetization of new initiatives.